论文部分内容阅读
目的探讨护肝片在防治抗结核药物所致肝损伤中的应用前景及疗效。方法对比分析治疗组与对照组之间在抗结核治疗中肝损害发生率、损害程度、发生时间,并进行差异显著性分析。结果 535例病例中,肝损害发生率为6.92%,治疗组ALT升高9例,发生率为3.37%,升高幅度在50~120U之间,损害多发生在治疗的2~4周,之后逐渐减少,HBsAg阳性病人发生率高,损害程度轻。对照组发生ALT升高28例,发生率为10.48%,升幅在75~180U之间,损害多发生于开始治疗4周左右,HBsAg阳性病人肝损害多为中重度损害,两组肝损害比较差异有统计学意义(χ2=9.34,P<0.01)。结论潜在的肝损害人群中,以HBsAg阳性人群和老年人群最为危险,在抗结核治疗中应全程加服护肝片,并密切注意肝功能的变化。
Objective To explore the foreground and curative effect of Hugan Tablets in the prevention and treatment of liver injury caused by anti-tuberculosis drugs. Methods The incidence of liver damage, the extent of injury and the time of occurrence of anti-TB therapy in treatment group and control group were compared and analyzed statistically. Results Among the 535 cases, the incidence of liver damage was 6.92%. In the treatment group, the ALT was increased in 9 cases with a rate of 3.37%. The increase ranged from 50 to 120 U and the damage occurred mostly within 2 to 4 weeks after treatment Gradually reduced, HBsAg-positive patients with high incidence of damage. ALT increased in control group 28 cases, the incidence was 10.48%, an increase of 75 ~ 180U, the damage occurred in the initial treatment of about 4 weeks, mostly HBsAg-positive liver damage in patients with moderate to severe damage, the two groups were significantly different liver damage There was statistical significance (χ2 = 9.34, P <0.01). Conclusion Among the potential liver damage groups, HBsAg positive population and elderly population are the most dangerous. In the anti-TB treatment, liver protection tablets should be added to the whole course of treatment, and pay close attention to the changes of liver function.